Boston Scientific Corporation (NYSE:BSX) reported fourth-quarter 2025 revenues of $5.29 billion on Wednesday, almost in line with the consensus estimate of $5.28 billion, beating the management guidance of $5.22 billion-$5.31 billion.

The medical technology giant reported adjusted earnings of 80 cents, beating the consensus of 78 cents and the management guidance of 77-79 cents.

Sales increased 15.9% on a reported basis, compared to the company's guidance range of 14.5%-16.5%, and 14.3% on an operational basis, 12.7% on an organic basis, compared to the company's guidance range of 11%-13%.

The company's cardiovascular segment generated sales of $3.48 billion, rising 18.2% (16.5% operationally and 16.1% organically).

Boston Scientific reported a 7% organic growth in interventional Cardiology & Vascular Therapies to $1.20 billion, Watchman sales increased to 29% to $535 million, Electrophysiology sales jumped 35% to $890 million, and Cardiac Rhythm Management sales were up 1% to $587 million.

MedSurg segment revenues increased to $1.81 billion, a 11.7% rise (10.2% operationally and 6.5% organically).

Endoscopy led the way with a 10.1% increase in sales of $760 million. Neuromodulation sales ...